Table 1.
Clinical data of the study patients and comparison by the presence of CBI.
| All (n = 15) | Without CBI (n = 7) | With CBI (n = 8) | p-Value | |
|---|---|---|---|---|
| Age (mean, SD) | 66.9 (11.9) | 67.5 (12.3) | 67.5 (12.3) | 0.852 |
| Women (n, %) | 10 (66.7%) | 4 (57.1%) | 4 (50%) | 0.608 |
| Smoking (n, %) | ||||
| Never smokers | 9 (60.0%) | 4 (57.1%) | 5 (62.5%) | >0.999 |
| Former smokers | 5 (33.3%) | 2 (28.6%) | 3 (37.5%) | |
| Current smokers | 1 (6.7%) | 1 (14.3%) | 0 (0%) | |
| Type of transplantation (n, %) | ||||
| Heart | 2 (13.3%) | 0 (0%) | 2 (37.5%) | 0.038 |
| Liver | 3 (20.0%) | 3 (42.9%) | 0 (0%) | |
| Kidney | 7 (46.7%) | 4 (57.1%) | 3 (37.5%) | |
| BMT | 3 (20.0%) | 0 (0%%) | 3 (37.5%) | |
| Months from transplantation to bronchiectasis diagnose (mean, SD) | 134 (98) | 184 (85) | 90 (90.5) | 0.061 |
| FEV1(mean, SD) | 93.3 (28.5) | 96.0 (40.4)) | 90.7 (44.7) | 0.744 |
| FEV1/FVC (mean, SD) | 71.1 (11.2) | 70.6 (26.3) | 71.6 (27.8) | 0.876 |
| Dyspnoea mMRC (median, IQR7) | 2 (1) | 1 (1.5) | 2 (1) | 0.467 |
| N° lobes (median, IQR) | 3 (3) | 3 (2) | 3 (2) | >0.999 |
| Exacerbations in the previous year (median, IQR) | 1 (2) | 1 (0.5) | 1 (2) | 0.569 |
| Admissions in the previous year (median, IQR) | 0 (1) | 0 (0) | 1 (1) | 0.282 |
| Microorganism IBC (n, %) | ||||
| None | 7 (46.7%) | 7 (100%) | 0 (0) | <0.001 |
| P. aeruginosa | 5 (33.3%) | 0 | 5 (62.5%) | |
| H. influenzae | 3 (20.0%) | 0 | 3 (37.5%) | |
| Azithromycin (n, %) | 3 (20.0%) | 1 (14.3%) | 2 (25%) | >0.999 |
| Inhaled antibiotic (n, %) | 5 (33.3%) | 0 (0%) | 5 (62.5%) | 0.026 |
| Inhaled treatment (n, %) | ||||
| None | 6 (40.0%) | 4 (57.1%) | 2 (25%) | 0.145 |
| LABA8 + LAMA | 1 (6.7%) | 1 (14.3%) | 0 (0) | |
| LABA + ICS | 4 (26.7%) | 2 (28.6%) | 2 (25%) | |
| LABA + LAMA + ICS | 4 (26.7%) | 0 (0) | 4 (50%) | |
| Oral glucocorticoids (n, %) | 9 (60.0%) | 3 (42.9%) | 6 (75%) | 0.315 |
| Tacrolimus (n, %) | 8 (53.3%) | 2 (28.9%) | 6 (75%) | 0.132 |
| Mycophenolate (n, %) | 11 (73.3%) | 6 (85.7%) | 5 (62.5%) | 0.569 |
| Everolimus (n, %) | 1 (6.7%) | 0 (0%) | 1 (6.7%) | >0.999 |
| BSI (mean, SD) | 7.7 (4.0) | 5.7 (2.8) | 9.4 (4.3) | 0.078 |
| E-FACED (mean, SD) | 2.6 (1.5) | 2 (0.8) | 3.1 (1.9) | 0.168 |
CBI: chronic bronchial infection; SD: standard deviation; BMI: bone marrow transplantation; FEV1: forced expiratory volume in the 1st second; FVC: forced vital capacity; mMRC: dyspnoea modified scale of the Medical Research Council; IQ: interquartile range; LABA: long-acting beta agonist; LAMA: long-acting antimuscarinic; ICS: inhaled glucocorticoid; BSI: bronchiectasis severity index.
Bold values denote statistical significance at the p <0.05 level.